A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Idelalisib (Primary) ; Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.